ImmuCell Corporation (ICCC) vs Neuraxis, Inc. (NRXS)
- ImmuCell Corporation ICCC 10.75 +1.80%
- Neuraxis, Inc. NRXS 7.70 −0.52%
ImmuCell Corporation and Neuraxis, Inc. are both Biotechnology companies. ImmuCell Corporation and Neuraxis, Inc. are of similar size ($97.2M and $95.9M). Neuraxis, Inc. has negative trailing earnings, so its P/E is not meaningful; ImmuCell Corporation trades at 126×. Neuraxis, Inc. grew revenue faster over the last twelve months: 65.2% against 8.49%. ImmuCell Corporation has the higher net margin (2.57% vs −159.0%) and the higher return on invested capital (7.84% vs 0.00%). Across the 18 metrics below, ImmuCell Corporation leads on 13 and Neuraxis, Inc. on 5.
Valuation
Profitability
| Metric | ICCC | NRXS | Biotechnology median |
|---|---|---|---|
| Gross margin | 40.32% | 85.56% | 65.16% |
| Operating margin | 12.60% | (144.51%) | 0.00% |
| Net margin | 2.57% | (159.01%) | 0.00% |
| Free cash flow margin | 13.79% | (106.10%) | 0.00% |
| Return on equity | 2.57% | (153.96%) | (56.36%) |
| Return on assets | 1.69% | (98.96%) | (48.04%) |
| Return on invested capital | 7.84% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack